Skip to Main Content
Contribute Try STAT+ Today

The National Agency for Medicines and Health Products in France has been indicted for “injuries and manslaughter through negligence” in connection with the availability of a Sanofi (SNY) epilepsy drug that has been linked to more than 400 congenital birth defects or stillborn births.

The indictment, which the regulator disclosed in a brief statement, is the latest development in a tumultuous scandal over the medicine, known as Depakine in France. Last August, the drug maker was indicted by French authorities for causing harm and failing to inform the public about the risks of taking the treatment during pregnancy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.